ETHNEM™ - 1.5GM

20ML WITH CARTON

ETHNEM™ - 1.5GM is a broad-spectrum antibiotic containing Meropenem and Sulbactam, used for treating severe bacterial infections. Meropenem, a carbapenem antibiotic, works by inhibiting bacterial cell wall synthesis, while Sulbactam enhances its efficacy by inhibiting beta-lactamase enzymes that bacteria use to resist antibiotics. This combination is particularly effective against multi-drug-resistant (MDR) bacteria and is commonly used in hospitals for life-threatening infections.

• While generally well-tolerated, ETHNEM™ - 1.5GM may cause some side effects, including:

• Common Side Effects
  • Nausea, vomiting
  • Diarrhea
  • Headache
  • Rash
  • Injection site reactions (pain, redness, swelling)
• Serious Side Effects (Rare but Critical)
  • Seizures (more common in patients with renal impairment)
  • Severe allergic reactions (anaphylaxis, angioedema)
  • Clostridium difficile-associated diarrhea
  • Liver enzyme elevation (Hepatitis, Jaundice)
  • Blood disorders (Neutropenia, Thrombocytopenia)

• If severe side effects occur, medical attention is required immediately.

   

• Administered intravenously (IV) in hospitals under medical supervision.
• Dosage depends on the severity of the infection, kidney function, and patient weight.
• Typically given every 8 hours as an IV infusion over 15-30 minutes.
• Must be prepared and administered by a healthcare professional.

• Key Considerations

• Renal Impairment: Dosage adjustment required.
• Neurotoxicity: Can cause seizures in patients with brain disorders.
• Antibiotic Resistance: Use only for confirmed bacterial infections to prevent resistance development.
• Clostridium difficile Risk: Can disrupt gut microbiota, leading to severe diarrhea.
• Superinfection Risk: Prolonged use may cause fungal or secondary bacterial infections.

ETHNEM™ - 1.5GM is contraindicated in:

• Patients with a known allergy to Meropenem, Sulbactam, or other beta-lactam antibiotics (Penicillins, Cephalosporins, Carbapenems).
• Individuals with a history of severe hypersensitivity reactions (Anaphylaxis, Steven-Johnson Syndrome).
• Severe renal failure without proper dose adjustment.
• Neonates and infants without medical consultation.

• ETHNEM™ - 1.5GM is contraindicated in:

• Patients with a known allergy to Meropenem, Sulbactam, or other beta-lactam antibiotics (Penicillins, Cephalosporins, Carbapenems).
• Individuals with a history of severe hypersensitivity reactions (Anaphylaxis, Steven-Johnson Syndrome).
• Severe renal failure without proper dose adjustment.
• Neonates and infants without medical consultation.

Standard Adult Dose

• Mild to moderate infections: 1.5g IV every 8 hours
• Severe infections (e.g., Meningitis, Pneumonia, Septicemia): 1.5-3g IV every 8 hours
• Renal Impairment: Dose adjustment based on creatinine clearance (CrCl)
• Children: Dose based on weight (as per doctor’s prescription)

• ETHNEM™ - 1.5GM may interact with:

• Valproic Acid & Divalproex: Can reduce valproic acid levels, increasing seizure risk.
• Probenecid: Delays Meropenem elimination, increasing toxicity risk.
• Other Beta-Lactam Antibiotics: Avoid combining with other carbapenems to prevent toxicity.
• Aminoglycosides (Gentamicin, Amikacin): Increased risk of nephrotoxicity.
• Blood Thinners (Warfarin): Can enhance anticoagulant effects, increasing bleeding risk.

• Do not self-administer; must be given by a healthcare professional.
• Complete the full course even if symptoms improve.
• Stay hydrated to minimize kidney-related side effects.
• Report any allergic reactions (rash, swelling, breathing issues) immediately.
• Inform the doctor of any ongoing medications, kidney disease, liver disease, or neurological conditions.

• Storage: Keep in a cool, dry place below 25°C. Protect from light and moisture.
• Reconstitution: Use sterile water or compatible IV fluids; use immediately after mixing.
• Prescription Required: Strictly administered under medical supervision.

• Clinical Infectious Diseases Journal – Guidelines on Carbapenem Use.
• World Health Organization (WHO) – Meropenem Drug Information.
• National Institutes of Health (NIH) – Drug Interaction and Safety Data.
• Indian Pharmacopoeia & FDA Guidelines – Approved Uses and Dosage.